


Cell Metabolism

Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis

Graphical Abstract



Authors

Nupur K. Das, Andrew J. Schwartz, Gabrielle Barthel, ..., Duxin Sun, Vincent B. Young, Yatrik M. Shah

Correspondence

shahy@umich.edu

In Brief

Das et al. show that gut microbiota regulate host iron metabolism. *Lactobacillus* species are the major bacterial players involved in sensing intestinal iron levels and attenuating host iron absorption. The authors further show that mammalian iron disorders can be therapeutically targeted by modulating microbial species or their metabolites.

Highlights

- *Lactobacillus* species sense intestinal iron levels and attenuate host iron absorption
- Microbial metabolites DAP and reuterin are novel HIF-2 α inhibitors
- Gut microbial metabolites regulate intestinal iron storage via ferritin regulation
- Gut microbiota can be therapeutically targeted for iron-related disorders

Microbial Metabolite Signaling Is Required for Systemic Iron Homeostasis

Nupur K. Das,¹ Andrew J. Schwartz,¹ Gabrielle Barthel,¹ Naohiro Inohara,² Qing Liu,⁹ Amanda Sankar,³ David R. Hill,⁸ Xiaoya Ma,¹ Olivia Lamberg,¹ Matthew K. Schnizlein,⁶ Juan L. Arqués,¹⁰ Jason R. Spence,^{4,8} Gabriel Nunez,² Andrew D. Patterson,⁹ Duxin Sun,⁷ Vincent B. Young,^{5,6} and Yatrik M. Shah^{1,8,11,*}

¹Department of Molecular & Integrative Physiology, University of Michigan, Ann Arbor, MI 48109, USA

²Department of Pathology and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA

³Department of Pediatrics, Division of Hematology-Oncology, University of Michigan, Ann Arbor, MI 48109, USA

⁴Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, MI 48109, USA

⁵Department of Internal Medicine, Division of Infectious Disease, University of Michigan, Ann Arbor, MI 48109, USA

⁶Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI 48109, USA

⁷College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA

⁸Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, MI 48109, USA

⁹Department of Veterinary and Biomedical Sciences, the Pennsylvania State University, University Park, PA 16802, USA

¹⁰Departamento Tecnología de Alimentos, INIA, Carretera de La Coruña Km 7, Madrid 28040, Spain

¹¹Lead Contact

*Correspondence: shahy@umich.edu

<https://doi.org/10.1016/j.cmet.2019.10.005>

SUMMARY

Iron is a central micronutrient needed by all living organisms. Competition for iron in the intestinal tract is essential for the maintenance of indigenous microbial populations and for host health. How symbiotic relationships between hosts and native microbes persist during times of iron limitation is unclear. Here, we demonstrate that indigenous bacteria possess an iron-dependent mechanism that inhibits host iron transport and storage. Using a high-throughput screen of microbial metabolites, we found that gut microbiota produce metabolites that suppress hypoxia-inducible factor 2 α (HIF-2 α) a master transcription factor of intestinal iron absorption and increase the iron-storage protein ferritin, resulting in decreased intestinal iron absorption by the host. We identified 1,3-diaminopropane (DAP) and reuterin as inhibitors of HIF-2 α via inhibition of heterodimerization. DAP and reuterin effectively ameliorated systemic iron overload. This work provides evidence of intestine-microbiota metabolic crosstalk that is essential for systemic iron homeostasis.

INTRODUCTION

Most organisms require iron to survive. Because of its unique redox chemistry, iron is critical for fundamental cellular biochemical processes. As both deficiency and excess of iron have deleterious effects, physiological iron homeostasis is tightly regulated. Mammalian iron acquisition is mediated by duodenal enterocytes via an integrative systemic and local regulatory system. Intestinal iron absorption is mainly regulated by hypoxia-inducible factor (HIF)-2 α , an oxygen- and iron-regulated transcriptional factor that directly targets the three key intestinal iron transporters; divalent metal transporter 1 (DMT1), duodenal cytochrome b (Dcytb), and ferroportin (FPN) (Shah et al., 2009; Taylor et al., 2011). The importance of hypoxia signaling and the essentiality of HIF-2 α in iron homeostasis have been highlighted in several genetic and pathophysiologic mouse models (Anderson et al., 2013; Das et al., 2015; Ramakrishnan et al., 2015; Xue et al., 2012). Ferritin (FTN), the major protein for cellular iron storage, acts as a source of bioavailable iron and detoxifying agent under conditions of cellular iron deficiency and excess, respectively (Harrison and Arosio, 1996). In addition, duodenal FTN regulates iron efflux into the circulation (Vanoica et al., 2010). The hepatic hormone hepcidin, known as the master regulator of iron homeostasis, regulates iron flux in peripheral tissues by degrading FPN, the only known mammalian iron

Context and Significance

Iron is an element essential for almost all living organisms. Interestingly, both iron deficiency and excess are harmful and lead to globally important diseases such as anemia and iron overload. The intestine hosts a diverse indigenous microbial population known as gut microbiota, which relies on the iron coming from the host's diet for its survival. Here, researchers at the University of Michigan show that *Lactobacillus* bacteria can sense intestinal iron levels and attenuate intestinal iron absorption by the host. Using relevant mouse models, the authors further show that mammalian iron disorders such as iron deficiency anemia and iron overload can be therapeutically targeted by administering microbial species or regulating their metabolites.




Figure 1. Gut Microbiota Suppress Iron-Absorptive Genes and HIF-2 α Expression

(A and B) Schematic of iron diet treatment (350-, 35-, and <5-ppm iron) in specific pathogen-free (SPF) and germ-free (GF) C57BL/6J mice (A) and complete blood count (CBC) (B).

(C) A general schematic of host intestinal iron regulation.

(D) Duodenal *Dmt1* and *Dcytb* gene expression in SPF and GF mice on 350-, 35-, and <5-ppm iron diets.

(E and F) Schematic of conventionalization of GF gut (GF-conv) by SPF fecal suspension (E) and duodenal *Dmt1* and *Dcytb* gene expression analysis of GF and GF-conv mice (F). Dotted lines indicate the corresponding mean gene expression values from SPF mice.

(legend continued on next page)

exporter. Recently, we showed that the hepcidin-FPN axis is essential for intestinal HIF-2 α activation and proper response following an increase in iron demand (Schwartz et al., 2019).

The human intestine is host to a complex symbiotic microbial community. The intestinal microbiota relies on host factors and resources for survival and in turn is closely linked to human health and disease (Lin and Zhang, 2017; Martin et al., 2018; Pickard et al., 2017; Wang et al., 2011). Effective nutrient acquisition in the competitive environment of the human gut is essential for persistence of indigenous microbes. The importance of iron as a nutrient for microbial growth is well established and underscored by the association of iron with the growth and virulence of a wide range of pathogens (Constante et al., 2017; Jaeggi et al., 2015). Microbiota have evolved efficient strategies to acquire iron; however, it is not clear how they compete with their hosts for limited iron during times of nutrient scarcity. Moreover, the role of the microbiota in intestinal iron absorption and systemic iron homeostasis has not been studied.

In this study, we show that gut microbiota regulate systemic iron homeostasis in the host in two ways: by repressing intestinal iron absorptive pathways via the inhibition of basal HIF-2 α function and by promoting cellular iron storage via the induction of FTN expression. Our results indicate that the host iron-sensing mechanism is intimately connected to and regulated by the gut microbiome. Intestinal iron deficiency leads to positive selection for a specific group of bacteria that produce metabolites that suppress HIF-2 α and induce FTN. We identify two gut microbial metabolites, reuterin and 1,3-diaminopropane (DAP), which effectively suppress intestinal HIF-2 α activity both *in vitro* and *in vivo*. Both of these metabolites prevent HIF-2 α dimerization with aryl hydrocarbon receptor nuclear translocator (ARNT) and thus prevent tissue-iron accumulation in a mouse model of iron overload.

RESULTS

Gut Microbiota Restrict Iron Absorption by Inhibiting HIF-2 α Expression

To understand the role of gut microbiota in host systemic iron homeostasis, we assessed the hematological response of C57BL/6J germ-free (GF) mice to dietary iron restriction. Three groups of GF mice were fed different iron diets—enriched (350 ppm iron), sufficient (35 ppm iron), or deficient (<5 ppm iron)—for 2 weeks and then compared with wild-type C57BL/6J-specific pathogen-free (SPF) mice that were fed the same diets (Figure 1A). Complete blood count (CBC) analyses demonstrated that SPF mice that were fed the <5-ppm diet were more anemic than GF mice that were fed the same diet (Figure 1B). Interestingly, there was no difference in serum iron measurements between the SPF and GF mice across the dietary groups (Figure S1A). Compared with those in the respective SPF control mice, the liver and spleen iron levels were significantly lower in the GF

mice that were fed the 350- or the 35-ppm diet but significantly higher in the GF mice that were fed the <5-ppm diet (Figure S1A). These results imply that indigenous gut microbial populations are in competition with the host for iron, which becomes more apparent in iron-limited conditions.

We analyzed hepatic hepcidin mRNA expression to investigate the systemic response to iron deficiency in GF mice. Hepcidin expression in the GF mice showed iron-dependent downregulation similar to that in SPF mice (Figure S1B). Moreover, hepcidin expression in SPF mice that were given a broad-spectrum antibiotic cocktail (Abx) in their drinking water for 2 weeks was not significantly different than that in control mice that did not receive antibiotics (Figure S1C). The duodenum is the primary site for dietary iron absorption, and HIF-2 α is the master regulator of intestinal iron homeostasis. HIF-2 α is essential for the regulation of the apical transporters DMT1 and Dcytb as well as that of FPN (Shah et al., 2009) (Figure 1C). In conditions of high iron demand, mRNA expression of those transporters is induced as part of a feedback mechanism (Shah et al., 2009; Taylor et al., 2011). *Dmt1* and *Dcytb* mRNA levels were induced by dietary iron deficiency in SPF mice (Figure 1D). Furthermore, *Dmt1* and *Dcytb* expression levels were highly potentiated in iron-deficient GF mice (Figure 1D). *Dmt1* and *Dcytb* expression levels in GF mice were also significantly higher in the basal iron conditions (350- and 35-ppm diets) than in the respective SPF cohorts (Figures S1D and S1E).

To confirm the role of the gut microbiota in the regulation of *Dmt1* and *Dcytb* expression, GF mice on the 350-ppm iron diet were conventionalized with the gut microbiota from healthy SPF mice on the same diet (GF-conv) given by a single oral gavage of fecal suspension (Figure 1E). GF-conv mice exhibited significantly lower CBC values than the GF cohort (Figure S1F). The *Dmt1* and *Dcytb* mRNA levels in the GF-conv mice were also significantly lower than those in GF controls and were comparable to those in SPF mice (Figure 1F). To further confirm the role of the gut microbiota in the expression of *Dmt1* and *Dcytb*, SPF mice on standard chow diet (containing 270-ppm iron) were given Abx in drinking water for 2 weeks to deplete their gut microbiota. The levels of *Dmt1* and *Dcytb* mRNA expression were significantly higher in the Abx-treated mice than in control mice that were not given Abx (Figure 1G). It is important to note here that Abx treatment resulted in a lower induction in *Dmt1* and *Dcytb* mRNA expression than what is observed in GF mice, most likely due to relatively very brief exposure of Abx to the host gut. Iron deficiency only regulates iron-related HIF-2 α target genes and has no regulatory effect on proinflammatory or angiogenic genes (Schwartz et al., 2019). Consistent with that, GF mice did not demonstrate an increase in HIF-2 α -dependent proinflammatory mediators (*Tnf α* , *Cxcl1*, *Ccl20*, *Il1 β* , and *Steap4*) in response to iron deficiency. Moreover, there was no significant difference in the expression of HIF-2 α -independent iron-related genes (transferrin receptor 1

(G) SPF mice fed with the standard chow diet (270-ppm iron) were depleted of microbiota by a broad-spectrum antibiotic cocktail in the drinking water (Abx) and duodenal *Dmt1* and *Dcytb* gene expression analysis.

(H) Wild-type (*Hif2 α ^{F/F}*) and intestine-specific HIF-2 α knockout (*Hif2 α ^{ΔI5}*) mice were treated with Abx, and duodenal *Dmt1* and *Dcytb* gene expression analyses shown.

(I) Immunohistochemical analysis of HIF-2 α in SPF, GF, and GF-conv duodenum. Intestine-specific VHL knockout (*Vhl^{ΔI5}*) was used as a positive control. All data are mean \pm SEM. One-way ANOVA with Tukey's multiple comparisons test (B), (D), and (H) or t test (F) and (G). * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 2. Microbial Metabolites Decrease HIF-2 α Expression and Activity

(A and B) Schematic of duodenal metabolite extraction from wild-type SPF mice and HIF-2 α expression assay in intestinal cell lines (A) and HIF-2 α western analysis of DFO or 1% O₂-pretreated (4 h) HCT116 cells followed by treatment with duodenal extracts (Ext) for 16 h (B). (C–E) Schematic of aqueous and organic extraction of duodenal and fecal metabolites from wild-type SPF mice and HIF-2 α expression assay in intestinal cell lines (C). HIF-2 α western analysis (D and E) in DFO- or 1% O₂-treated HCT116 cells or co-treated with organic extracts (Ext) for 16 h. (F) HIF-2 α western analysis in DFO-treated HCT116 cells co-treated with Ext, heated (95°C) Ext (Ext(H)) (upper panel) or trypsin-digested Ext (Ext(T)) (lower panel) from fecal organic extracts. (G) HIF-2 α western analysis in DFO-treated HCT116 cells or co-treated with organic (upper panel) and aqueous (lower panel) extracts from GF and GF-conv feces. (H) HIF response element (HRE)-based luciferase assay (HRE-Luc) in HCT116 cells transfected with empty vector (control) or HIF-2 α , followed by treatment with vehicle (DMSO) or fecal organic extracts from SPF (SPF-met) and GF (GF-met) mice (n = 3).

(legend continued on next page)

(*Tfr1*), lipocalin2 (*Lcn2*), and hephastin (*heph*) between GF mice and SPF mice (Table S1). Interestingly, ankyrin repeat domain 37 (*Ankrd37*), a well-known but less-characterized HIF target, (Benita et al., 2009) and *Arnt*, the heterodimeric partner of the HIF- α subunit, were further induced in iron-deficient GF mice (Table S1). In addition, the gut microbiota did not alter the expression of iron-regulatory genes in peripheral tissues (Table S1). To confirm the involvement of HIF-2 α in the gut microbiota-mediated regulation of intestinal iron transporters, mice with a disruption of HIF-2 α specifically in intestinal epithelial cells (*Hif2 α ^{ΔIE}*) and their wild-type littermates (*Hif2 α ^{F/F}*) were treated with Abx for 2 weeks. *Dmt1* and *Dcytb* expression was significantly induced in the *Hif2 α ^{F/F}* mice, but the effect was completely abolished in the *Hif2 α ^{ΔIE}* mice (Figure 1H). Immunohistochemical analysis of GF duodenal epithelia revealed robust HIF-2 α expression, which was even higher than that observed in intestine-specific VHL-deleted (*Vhl^{ΔIE}*) duodenum, a well-established model of intestinal HIF overexpression (Taylor et al., 2011). Also, the conventionalization of GF mice reduced HIF-2 α expression to levels observed in SPF mice (Figure 1I). Together, these results demonstrate that gut microbiota suppresses basal HIF-2 α expression and activity in the small intestine.

Microbial Metabolites Inhibit HIF-2 α Expression and Function

To explore the underlying mechanism of gut microbiota-mediated inhibition of HIF-2 α expression and function, human pluripotent stem cells (hPSCs) were used to generate human intestinal organoids (HIOs) (Finkbeiner et al., 2015), and a non-pathogenic commensal *Escherichia coli* strain was then microinjected into the HIO lumen (Figure S2A) (Hill et al., 2017). Contrary to our *in vivo* findings, we observed robust induction of HIF-2 α expression in HIOs injected with live bacteria but not in HIOs injected with heat-inactivated bacteria (Figure S2B). Consistent with the observed upregulation of the HIF-2 α protein, the RNA expression of the HIF-2 α -target apical iron transporters *DMT1* and *DCYTB* was also robustly induced by live bacteria in HIOs (Figure S2C). Expression analysis of inflammatory genes such as *TNF α* , *IL1 β* , *IL8*, *CXCL1*, *CXCL2*, and *CCL20* suggests that there was generalized induction of the HIF pathway in the HIOs (Figure S2D). This is consistent with previous studies demonstrating the role of microbiota in the establishment of the luminal oxygen gradient *in vivo*, suggesting a mechanism of intestinal HIF-2 α repression that is independent of oxygen levels (Albenberg et al., 2014).

The HIO-microbiota co-cultures are informative of bacterial sensing pathways, but they are mostly devoid of hetero-cellular metabolite communication, as many of the abundant microbial metabolites are derived from the host diet (Shankar et al., 2017; Wikoff et al., 2009). To investigate the possible role of microbial metabolites in HIF-2 α regulation, crude extracts were isolated from duodenal contents using methanol-H₂O (80:20 v/v) as described previously (Bennett et al., 2008) (Figure 2A) and used to treat HCT116 human intestinal epithelial cells for 16 h, with or

without treatment with deferoxamine (DFO) (a well-known iron chelator) or hypoxia (1% O₂). DFO and hypoxia both induced HIF-2 α expression that was repressed by the duodenal metabolite extracts (Figure 2B). These results suggest that the gut lumen harbors small metabolites that are responsible for attenuation of the HIF-2 α response.

To explore the physicochemical properties of the gut extracts, organic and aqueous phases were isolated from both duodenal and cecal (feces) contents by methanol-chloroform-water extraction (Figure 2C). Since it has already been shown (Figure 2B) that duodenal extracts possess the HIF-2 α inhibitory properties in iron-deficient or hypoxic conditions, we tested the duodenal organic extracts in the presence of DFO and observed that they inhibited HIF-2 α induction in HCT116 cells in a dose-dependent manner (Figure 2D). Similar results were obtained from the fecal organic extracts (Figure 2E). The duodenal and fecal aqueous extracts had significantly less repressive activity than the organic extracts (Figures S2E and S2F). Moreover, the fecal organic extracts had no effect on DFO-induced HIF-1 α expression in HCT116 cells (Figure S2G), confirming the HIF-2 α -specific effects of the gut luminal extracts. To rule out the presence of any small proteins or peptides, fecal organic extracts were subjected to trypsin digestion or heating at 95°C, neither of which abolished the HIF-2 α -repressive function of the extracts (Figure 2F). To investigate whether the HIF-2 α inhibitory compounds in the gut extracts are microbial in origin, organic and aqueous phase extracts were isolated from GF and GF-conv mice. Strikingly, only the organic extracts of the GF-conv mice, but not that of the GF, downregulated the DFO-mediated HIF-2 α induction, confirming that the HIF-2 α inhibitory compounds are microbial in origin (Figure 2G).

To further confirm the role of gut microbiota in HIF-2 α function, *Dmt1* promoter activity was analyzed by HIF response element (HRE)-based luciferase (HRE-Luc) assay after transient HIF-2 α overexpression in HCT116 cells followed by treatment with fecal extracts from SPF or GF mice (termed SPF metabolites and GF metabolites, respectively). Consistent with the protein expression data, the SPF metabolites significantly inhibited HRE-Luc activity, whereas the GF metabolites had no significant effect (Figure 2H). In a similar experiment, HRE-Luc activity was used to investigate the impact of gut microbiota on HIF-1 α function. There was no significant difference between SPF metabolites and GF metabolites with regard to HIF-1 α function (Figure S2H). To identify compounds that might be responsible for the inhibition of HIF-2 α activity and function, we generated a library of the 66 most abundant gut microbial metabolites according to a recent study (Matsumoto et al., 2012) (Table S2). These compounds and live and heat-killed bacterial components were screened on the basis of HRE-Luc activity assay in HCT116 cells. The screen identified 12 compounds that significantly inhibited HIF-2 α . Further analysis revealed that 9 compounds were toxic at doses at or below the range of physiological concentrations in the gut lumen (Malo, 1994; Parsons and Shaw, 1983; Schott

(I) Metabolite screen for HIF-2 α suppression based on HRE-Luc assay in HCT116 cells.

(J) HIF-2 α western analysis in DFO-treated or co-treated with butyrate, propionate, and 1,3-diaminopropane (DAP) HCT116, HT29, and SW480 cells.

All data are mean \pm SEM. One-way ANOVA with Tukey's multiple comparisons test (H) and (I).

Western analyses (B), (D), (E), (F), (G), and (J); images were analyzed by ImageJ software from three independent experiments, representative image shown. Statistical significance compared with DFO-only or 1% O₂-only (B) and (E) treatment group. *p < 0.05, ***p < 0.001.




Figure 3. Microbial Metabolites Sustain Intestinal- and Peripheral-Tissue Ferritin (FTN) Expression

(A–E) FTN western analyses in (A) duodenum, liver, and spleen of SPF versus GF mice fed with the 350-, 35-, or <5-ppm iron diet and duodenum of control or Abx-treated, (B) wild-type (*Hif2α^{F/F}*) and intestine-specific HIF-2α knockout (*Hif2α^{ΔIE}*) mice, (C) wild-type (*Ncoa4^{+/+}*) and NCOA4 knockout (*Ncoa4^{-/-}*) mice, (D) wild-type (*Tlr2,4^{+/+}*) and TLR2,4 double knockout (*Tlr2,4^{-/-}*) mice, and (E) wild-type (*Myd88^{+/+}*) and Myd88 knockout (*Myd88^{-/-}*) mice. (F) FTN western analysis of ferric ammonium citrate (FAC) (10 μM) -pretreated HT29 cells followed by dose-dependent treatment of fecal metabolites from wild-type SPF mice.

(G) Schematic showing Abx treatment of wild-type C57BL/6J mice followed by intraperitoneal (i.p.) injection of fecal metabolites (Ext).

(H) FTN western blot analyses of duodenum, liver, and spleen of control or Abx-treated mice fed with the 350- and 35-ppm iron diets (left panel) and Abx- or Abx plus Ext-treated mice fed with the 350-ppm iron diet (right panel).

All data are mean ± SEM. Western analysis (A–F) and (H), images were analyzed by ImageJ software from three independent experiments, representative image shown. Statistical significance compared within the respective groups (A–E) and (H) and FAC-only control (F). *p < 0.05.

gously, Abx treatment of wild-type mice drastically decreased the DAP concentration (Figure S3D). Moreover, DAP treatment at a dose range of 0–50 μM did not show any obvious signs of toxicity and did not significantly affect cell growth (Figure S3E). 1,2-diaminopropane (1,2-DAP), which is not microbially derived, did not alter HIF-2α expression (Figure S3F). Acetate, an abundant gut microbial metabolite, had only a marginal effect on HIF-2α

et al., 1983) (Figure 2I). Thus, we narrowed our search to three metabolites: butyrate, propionate, and DAP. Further dose-dependent analysis of these three compounds in HCT116, HT29, and SW480 cells confirmed that the compounds inhibit HIF-2α expression at the protein level (Figure 2J). The lowest effective doses of butyrate, propionate, and DAP that inhibited HIF-2α *in vitro* were 0.5 mM, 2.5 mM, and 5 μM, respectively (Figure 2J). The minimal inhibitory concentration of butyrate exceeded what is observed in the duodenum, whereas that of propionate and DAP were within the physiological range (Figures S3A and S3B). Butyrate and propionate are well-characterized microbial metabolites present in mouse and human, but DAP has not been assessed rigorously. We now show that DAP was detected in both human and mouse guts in comparable concentrations (Figure S3B). Although DAP is detected in the GF mouse gut (duodenum, ≈ 4 μM and colon, ≈ 10 μM), its concentration increased by several-fold following conventionalization (>5-fold in the duodenum, 25 μM and ≈ 10-fold in the colon, 100 μM), demonstrating a microbial contribution (Figure S3C). Analo-

gously, Abx treatment of wild-type mice drastically decreased the DAP concentration (Figure S3D). Moreover, DAP treatment at a dose range of 0–50 μM did not show any obvious signs of toxicity and did not significantly affect cell growth (Figure S3E). 1,2-diaminopropane (1,2-DAP), which is not microbially derived, did not alter HIF-2α expression (Figure S3F). Acetate, an abundant gut microbial metabolite, had only a marginal effect on HIF-2α

Microbial Metabolites Are Essential for FTN Expression

A third integral component in the regulation of intestinal iron absorption and systemic iron homeostasis is the iron-storage protein FTN. In a previous study, intestinal FTN disruption led to an increase in iron absorption (Vanoaica et al., 2010). FTN expression in the GF duodenum was significantly lower than that in the SPF duodenum in basal iron conditions (350- and 35-ppm iron diets), whereas in the liver and spleen the effect was more pronounced with the 35-ppm iron diet (Figure 3A).




Figure 4. DAP Suppresses HIF-2 α Activity In Vivo via Blocking Heterodimerization

(A and B) Duodenal *Dmt1* and *Dcytb* gene expression in C57BL/6 wild-type SPF mice (A) fed with 350- or <5 ppm iron diet and treated with 1,3-diaminopropane (DAP) in drinking water (2 g/L) for 2 weeks or (B) treated with antibiotic cocktail (Abx) and/or DAP in drinking water for 2 weeks.

(C) HIF-2 α western analysis of DFO-treated HCT116 and HEK293 cells followed by PT2385 treatment.

(D) Schematic of co-immunoprecipitation protocol for determination of the roles of DAP or PT2385 in the HIF-2 α -ARNT interaction.

(E) Co-immunoprecipitation for ARNT and HIF-2 α in HEK293T cells treated with DAP (50 μ M) or PT2385 (10 μ M); relative densitometric analysis of four independent experiment shown on the right panel.

(F and G) Schematic (F) and (G) experimental representation of DAP- or PT-mediated HIF-2 α -ARNT interaction by pG5GAL4 luciferase assay followed by pBIND-HIF-2 α and/or pACT-ARNT transfection of HEK293 cells (n = 3).

(H) Schematic showing the effect of PT2385 or PT2399 (PT) on the HIF-2 α -ARNT interaction and the effect on the same following the mutation of PT2385- or PT2399-binding sites on HIF-2 α .

(legend continued on next page)

FTN expression in the duodenum, liver, and spleen was significantly reduced in antibiotic-treated mice (Figure 3H, left panel). Duodenal FTN expression rapidly returned to the basal level in GF-conv mice (Figure S4A). There was no significant change in *Ftn* mRNA expression in the GF duodenum, which rules out transcriptional regulation by gut microbiota (Figure S4B).

To explore further, we utilized a model of gut microbiota depletion by Abx treatment in several genetic mouse models. In intestine-specific HIF-2 α knockout (*Hif2 α ^{ΔIE}*) mice, the Abx treatment decreased duodenal FTN protein expression, confirming that the regulation of FTN by gut microbiota is HIF-2 α independent (Figure 3B). NCOA4 mediates lysosomal degradation of FTN by a process known as ferritinophagy (Mancias et al., 2014). NCOA4-deficient cells show increased FTN expression due to a lack of FTN processing. Upon Abx treatment, the *Ncoa4*^{-/-} duodenum showed a rate of FTN decrease similar to that in wild-type controls (Figure 3C). Similarly, Abx treatment decreased FTN expression in both *Tlr2,4*^{-/-} and *Myd88*^{-/-} mice, ruling out the involvement of major bacterial sensing pathways (Figures 3D and 3E).

We next investigated the effects of butyrate, propionate, and DAP on FTN regulation. Those metabolites did not cause a significant change in basal or iron (ferric ammonium citrate (FAC))-induced FTN expression in intestinal epithelial cell lines (Figures S4C and S4D). To explore the possibility that a novel group of metabolites was involved, we utilized metabolites extracted from feces of healthy SPF mice. Interestingly, the crude metabolites were able to induce FTN expression in iron-stimulated intestinal epithelial cell lines in a dose-dependent manner (Figure 3F). To investigate the systemic effects of the metabolites, we introduced the metabolites into antibiotic-treated mice by intraperitoneal (i.p.) injection (Figure 3G). FTN expression in the duodenum, liver, and spleen increased in the mice that were treated with the metabolites, suggesting that novel, unidentified microbial metabolite(s) play a role in systemic FTN regulation (Figure 3H, right panel).

DAP Suppresses Iron-Deficiency-Induced and Antibiotic-Induced HIF-2 α Activity by Blocking HIF-2 α Heterodimerization

Because DAP, butyrate, and propionate effectively inhibited HIF-2 α expression and activity *in vitro*, we next asked if those metabolites had any role in the suppression of HIF-2 α activity in an *in vivo* setting. Mice on the 350- or <5-ppm iron diet were given DAP (2 g/L) (Salim et al., 2000) in drinking water for 2 weeks. The expression of the HIF-2 α -target apical iron transporters *Dmt1* and *Dcytb* was robustly induced by iron deficiency, and DAP administration significantly attenuated the response (Figure 4A). In addition, antibiotic-induced HIF-2 α expression and function were also abrogated following the administration of DAP (Figure 4B). Similar experiments were performed to assess butyrate and propionate, but those metabolites could not suppress HIF-2 α function *in vivo* (Figures S5A and S5B). Analysis of *Hif2 α*

mRNA expression in HCT116 cells treated with fecal metabolites from GF, GF-conv, or SPF mice revealed no significant difference among the treatment groups (Figure S5C). Butyrate and propionate increased *Hif2 α* mRNA expression in HCT116 cells while DAP treatment had no significant effect, demonstrating that gut microbiota-mediated HIF-2 α inhibition is independent of mRNA changes. (Figure S5D).

The 5' UTR of HIF-2 α harbors an iron response element (IRE), rendering it amenable to iron-regulatory protein (IRP)-mediated translational inhibition (Sanchez et al., 2007). To determine if butyrate, propionate, or DAP inhibit HIF-2 α via an IRE-dependent mechanism, we performed a HIF-2 α -IRE-based luciferase assay in HCT116 cells. In contrast to their effects on HIF-2 α protein expression, the metabolites strongly increased HIF-2 α -IRE activity, ruling out the possibility of an IRE-dependent mechanism (Figure S5E). The PAS-B domain of HIF-2 α contains a hydrophobic cavity that resembles a ligand-binding pocket. PT2385 selectively with high affinity binds to this cavity and disrupts HIF-2 α heterodimerization with ARNT (Wallace et al., 2016). Consistent with the literature, the disruption of HIF-2 α heterodimerization by PT2385 also decreased the HIF-2 α protein stability (Figure 4C) (Wallace et al., 2016). To determine if DAP inhibits HIF-2 α by a mechanism similar to that of PT2385, we performed co-immunoprecipitation assays to assess HIF-2 α -ARNT heterodimerization (Figure 4D). In agreement with the literature, PT2385 completely abrogated the HIF-2 α -ARNT interaction (Figure 4E) (Chen et al., 2016; Cho et al., 2016). DAP also significantly inhibited the HIF-2 α -ARNT interaction, although not to the extent of PT2385 (Figure 4E). To further verify the effect of DAP on the HIF-2 α -ARNT interaction, we utilized a mammalian two-hybrid system (Figure 4F). Consistent with the co-immunoprecipitation results, DAP inhibited the HIF-2 α -ARNT interaction in the two-hybrid system (Figure 4G). It was recently reported that treatment with allosteric PT inhibitors decreases clear-cell renal carcinoma growth; however, long-term treatment led to resistance via missense mutations (S304M and G323E) in the ligand-binding cavity of HIF-2 α (Chen et al., 2016; Cho et al., 2016). We generated double mutants of mouse HIF-2 α (S305M and G324E; Figure 4H) and performed HRE-Luc assays to assess the effect of the mutations on DAP-mediated HIF-2 α inhibition. Indeed, the mutations in the PT-binding sites completely rescued the inhibition (Figure 4I). Together, these data suggest that bacterial metabolites have the ability to act as endogenous ligands for HIF-2 α that suppress activity.

Limiting Iron Levels Lead to More Potent HIF-2 α Inhibition by Microbial Metabolites

To understand how the production of microbial metabolites is integrated with host iron sensing, we asked if dietary iron manipulation could modulate the HIF-2 α -suppressive function of microbial metabolites. HCT116 cells were treated with fecal metabolites extracted from mice that had received 350-, 35-, or <5-ppm iron diets for 2 weeks (Figure 5A). The metabolites

(I) HEK293 cells were transfected with wild-type or PT-binding site mutant HIF-2 α followed by DAP or PT treatment and HRE-based luciferase assay was performed (n = 3).

All data are mean \pm SEM. One-way ANOVA with Tukey's multiple comparisons test (A), (B), and (E) and right panel (G) and (I). Western analyses (C), images were analyzed by ImageJ software from three independent experiments, representative image shown. Statistical significance compared with the DFO-only treatment group. *p < 0.05, **p < 0.01, ***p < 0.001.




Figure 5. Low-Iron Diet Potentiates HIF-2 α Inhibition by Microbial Metabolites

(A and B) Schematic of fecal metabolite extraction from SPF mice fed with 350-, 35-, and <5-ppm iron diets for 2 weeks (A) and (B) HIF-2 α western analysis in HCT116 cells treated with or without DFO and metabolites (350-, 35-, or <5-ppm, respectively).

(C) DAPI concentration in duodenum and feces from wild-type fed with 350- and <5-ppm iron diets for two weeks.

(D) Schematic of the experimental set up for bacterial community analysis.

(E) Principal-component analysis (PCA) of the fecal bacterial population from 16S rRNA sequencing data in mice fed with 350- and <5-ppm iron diets.

(F) 16S rRNA sequencing bacterial community analysis from duodenal content and feces.

(legend continued on next page)

isolated from the iron-deficient feces (<5 ppm) caused the most potent HIF-2 α inhibition (Figure 5B). This suggests that iron deficiency selectively favors the growth or production of microbes and metabolites that exert relatively high levels of HIF-2 α inhibition. However, there was no change in DAP concentration in iron-deficient mice (Figure 5C). In addition, iron deficiency rather decreased the gut concentration of butyrate and did not alter acetate and propionate levels (Figure S6A).

Given the tendency of iron deficiency to lead to the production of metabolites that inhibit HIF-2 α and no change in DAP levels in iron-deficient guts, we next focused on the identification of other metabolites that can inhibit HIF-2 α or are integrated with iron sensing. We first assessed changes in microbial communities due to luminal iron limitation (Figures 5D and 5E). Bacterial community analysis by 16S rRNA-encoding gene amplicon sequencing revealed *Lactobacillales* as the only bacterial genus showing a robust increase in relative abundance in response to iron limitation in both duodenal contents and feces (Figures 5F and 5G). We have analyzed a total of five different *Lactobacillus* species, and among them the relative abundance of both *Lactobacillus johnsonii* and *Lactobacillus reuteri* were both significantly increased in the duodenal contents and feces following iron deficiency (Figures 5H, 5I, and S6B). Also, a human isolate of *L. reuteri* showed increased abundance with increasing concentrations of DFO, whereas *E. coli* showed less abundance in the same conditions (Figure S6C). We were able to detect *Lactobacilli* and specifically *L. reuteri* in the duodenal aspirates from healthy humans (Figures S6D and S6E). Together, these data suggest that limiting the iron level favors the growth of a specific bacterial population, which might be producing metabolite(s) responsible for intestinal HIF-2 α suppression.

Intestinal Reuterin Suppresses HIF-2 α Activity via Blocking Heterodimerization

3-hydroxypropionaldehyde (reuterin) is produced by *L. reuteri*, and little is known about its role in gut physiology other than its role as an antimicrobial compound (Schaefer et al., 2010) (Figure 6A). To produce reuterin, *L. reuteri* relies on a glycerol dehydratase-dependent metabolism of glycerol, which is only seen in bacteria (Chen and Chen, 2013). Reuterin is mostly undetected in the GF gut and its concentration robustly increased following conventionalization (Figure 6B). Analogously, Abx treatment drastically brought down the intestinal reuterin concentrations (Figure S7A). Physiological reuterin levels range from 250 μ M in the proximal small intestine to greater than 1 mM in the colon (Figure 6C). Reuterin levels were robustly increased in mice that received a <5-ppm iron diet for 2 weeks compared with those in mice that received a 350-ppm iron diet (Figure 6C). Reuterin treatment led to a dose-dependent decrease of HIF-2 α (but not HIF-1 α) expression and activity in human intestinal epithelial cell lines (Figures 6D, 6E, S7B, and S7C). Similar to DAP, reuterin significantly disrupted the HIF-2 α -ARNT interaction (Figure 6F). HRE-Luc assay with the PT-binding mutant sites of HIF-2 α showed a complete reversal of reuterin-mediated inhibition (Figure 6G).

Treatment with Probiotics or Antibiotic Improved Iron-Related Disorders in Mouse Models

Given the *in vitro* and *in vivo* findings with our two novel HIF-2 α -specific inhibitors, DAP and reuterin, we next asked whether those inhibitors could play any therapeutic roles in iron-overload disorders. The most common cause of iron-overload disorders is dysregulation of the hepcidin-FPN axis. We developed a temporal model of iron overload in a tamoxifen-inducible hepatic hepcidin knockout mouse model (*Hamp*^{ΔLiv}) (Schwartz et al., 2019). The knockout mice showed rapid tissue accumulation of iron as early as 4 weeks following tamoxifen treatment (Figure 7A) (Schwartz et al., 2019). We provided the DAP or *L. reuteri* probiotic suspension (as source of reuterin) in drinking water to *Hamp*^{ΔLiv} mice for 2 weeks prior to and for 2 more weeks following tamoxifen injection. Sufficient *L. reuteri* growth during the probiotic treatment was confirmed by bacteria-specific PCR using fecal DNA, showing that the size of the *Lactobacilli* population increased by about 25-fold (Figure S7D). Treatment with the *L. reuteri* probiotic resulted in robust production of reuterin in the intestine (Figure S7E). Quantitative iron assays revealed that the DAP treatment caused significant decreases in iron levels in the liver, pancreas, and heart in *Hamp*^{ΔLiv} mice compared with the levels in DAP-treated wild-type controls (*Hamp*^{fl/fl}), whereas *L. reuteri* probiotic treatment caused significant decreases in the pancreas and heart but not in the liver (Figure 7B). We previously showed that temporal disruption of hepatic hepcidin activates intestinal HIF-2 α (Schwartz et al., 2019). Western analysis showed a robust increase in the levels of HIF-2 α -dependent intestinal iron transporters (DMT1, Dcytb, and FPN) in vehicle-treated *Hamp*^{ΔLiv} mice compared with those in wild-type control mice. That response was abrogated in *Hamp*^{ΔLiv} mice that were treated with the DAP or *L. reuteri* probiotic (Figure 7C). In contrast, activation of HIF-2 α would lead to an increase in intestinal iron absorption and treat anemic disorders. Reuterin and DAP levels are observed in the small intestine and can be significantly decreased by Abx intervention to inhibit commensals and/or HIF-2 α -suppressive metabolites may improve anemia. To determine if antibiotics would provide any benefit in anemic mouse models, rifaximin was assessed. Rifaximin is a gut-specific antibiotic due to its poor absorption when taken orally (Ma et al., 2007). Rifaximin did not activate HIF-2 α or chelate iron in cell lines (Figures S7F and S7G). Rfx treatment decreased both *L. johnsonii* and *L. reuteri* (Figure S7H) and increased the expression of iron-absorptive genes in mouse models of iron-deficient anemia (Figure 7D). Although hematocrit and hemoglobin values did not improve following 2 weeks of Rfx treatment, there was significant increase in mean corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin concentrations (MCHC), indicating an increase in RBC hemoglobinization. Increase in MCH is a reliable and early indicator of improvement of iron deficiency, a significant change usually occurs within a week's intervention (Goddard et al., 2011) (Figures 7E and S7I). Overall, our results show that microbiome-based therapeutics can be used to successfully treat iron-related disorders.

(G) Comparative analysis of the genus *Lactobacillales* by 97% sequence similarity (OTU97) values in duodenal content and feces.

(H and I) Comparative analysis of *L. johnsonii* and *L. reuteri* density by species-specific PCR from (H) duodenal content and (I) feces.

All data are mean \pm SEM. t test for the corresponding panels (C), (G), (H), and (I). Western analyses (B), images were analyzed by ImageJ software from three independent experiments, representative image shown. Statistical significance compared with the DFO-only treatment group. *p < 0.05, **p < 0.01.




Figure 6. Reuterin Suppresses HIF-2 α Activity via Blocking Heterodimerization

(A) Chemical structures of butyrate, propionate, DAP, and reuterin.

(B) Intestinal reuterin concentrations in GF and GF-conv mice.

(C) Mean physiological concentration of reuterin in the human duodenum and mouse intestine (left panel) and intestinal reuterin concentration in mice fed with the 350- or <5-ppm iron diet (right panel).

(D) HIF-2 α western analysis in DFO-treated HCT116, HT29, and SW480 cells or co-treated with reuterin.

(E) HRE-based luciferase assay in HCT116 cells transfected with empty vector (control) or HIF-2 α , followed by dose-dependent treatment of reuterin (n = 3).

(F) Modified two-hybrid assays in HEK293 cells transfected with pBIND-HIF-2 α and pACT-ARNT and treated with reuterin or PT2385 (PT) (n = 3).

(legend continued on next page)

DISCUSSION

In this study, we showed that gut microbial metabolites regulate host systemic iron homeostasis by suppressing intestinal HIF-2 α activity and upregulating FTN expression. We identified two HIF-2 α inhibitory microbial metabolites that effectively prevent tissue-iron accumulation in a mouse model of systemic iron overload. This is the first investigation that offers mechanistic insight into the crosstalk between the host and indigenous microbiota with regard to systemic iron homeostasis.

GF mice exhibited significant resistance to anemia following dietary iron restriction. Although this finding can be explained from the perspective of host-microbe competition, there was no significant difference in the hepcidin response between GF and control livers. This suggests that gut microbiota regulate host iron metabolism via a hepcidin-independent mechanism. Dietary iron deficiency in GF mice led to an unprecedented induction of HIF-2 α -target intestinal iron transporters, which was reproducible in an Abx-induced microbiota-depletion model. Consistent with those results, introduction of gut microbiota to GF mice was sufficient to restore basal levels of the intestinal iron transporters. While our *in vitro* organoid model failed to replicate the HIF-2 α -suppressive effect of the gut bacteria, we inquired whether that finding might be attributable to a microbial function that is intimately associated with host systemic homeostasis. Recently, there has been renewed interest in elucidating the novel roles of microbial metabolites in host intestinal homeostasis. Of note, previous reports described the role of butyrate (the most abundant SCFA metabolite in the gut) in gut homeostasis by stabilization of HIF-1 α (Fachi et al., 2019; Kelly et al., 2015). Gut extracts from only GF-conv (but not GF) mice were found to have HIF-2 α inhibitory properties, highlighting the essential role of microbiota in such regulation. Using a high-throughput assay of HIF-2 α activity to screen a library of highly abundant gut microbial metabolites, we identified several candidate HIF-2 α inhibitors. Among them, DAP suppressed intestinal HIF-2 α activity in at least two well-established mouse models of HIF-2 α induction; dietary iron deficiency and antibiotic-induced microbiota depletion. DAP, a polyamine, is produced in the gut by several bacterial species (Chae et al., 2015). DAP is also known to be synthesized in the gut independent of microbiota (Matsumoto et al., 2017). Conventionalization of GF mice and Abx treatment reciprocally caused highly significant changes, strongly indicating that microbiota is the major contributor of intestinal DAP levels. Although DAP is reported to have iron-scavenging properties, its relationship with intestinal iron availability has never been studied (Burrell et al., 2012). However, DAP was not shown to be integrated in host iron sensing. Bacterial community analysis revealed a robust increase in the intestinal abundance of the genus *Lactobacillales* during dietary iron deficiency. At the species level, *L. johnsonii* and *L. reuteri* populations (bacterial density relative to the total bacteria) were significantly induced by iron deficiency. It is important to note that while the relative *Lactobacillales* abundance and relative density of *Lactobacilli*

species were increased by iron deficiency, their absolute densities in the corresponding gut lumen were not determined. Also, the gut concentration of reuterin, a product of *L. reuteri*, increased robustly during iron deficiency. Similar to DAP, reuterin was found to have HIF-2 α inhibitory properties. Both metabolites required the ligand-binding pocket of HIF-2 α for inhibition. The role of the hydrophobic cavity on HIF-2 α was hitherto unknown and therefore was termed a pseudo-ligand-binding pocket. Our data suggest that selective bacterial metabolites are endogenous ligands that attenuate HIF-2 α activity. It is important to note here that the gut extracts contain innumerable amounts of metabolites, many of their identities and functions are yet to be determined. So, the physiological HIF-2 α inhibition following treatment with these pan-metabolite extracts is a collective and concerted effect, not necessarily only exerted by the metabolites identified in this work.

In agreement with previous reports, we could successfully detect *L. reuteri* in the human duodenum. Also, both DAP and reuterin were detected in the human duodenum at similar levels to that of mice. Given the finding that gut levels of reuterin and DAP can be effectively controlled by microbial presence (GF-conventionalization or Abx treatment), it strongly indicates that microbiota is the major source of these metabolites in the gut. It is important to note here that some of these metabolites (e.g., DAP) are also derived from dietary or environmental sources. In this work, we demonstrate that (1) a relevant bacterial population is present in both mouse and human guts, (2) their presence is necessary and sufficient for suppressing intestinal HIF-2 α function, (3) the metabolites are also present in both mice and humans, (4) the duodenal concentrations of the metabolites are directly regulatable by gut bacterial colonization, and (5) the duodenal concentration of reuterin is regulated by iron availability therein. However, we have not specifically pinpointed whether the metabolites detected in the duodenum are produced locally or originate more distally, e.g., from the cecum and colon. Given the vastly higher density of bacteria in the cecum and colon, it is possible that the relevant metabolites are absorbed into the portal circulation there and redistributed to the proximal GI tract.

Our results clearly demonstrate that oral supplementation of DAP and reuterin results in a decrease in iron accumulation in mouse models of hemochromatosis, making this the first study to report the discovery of microbially derived metabolites with clinical relevance to iron-related disorders. Moreover, our results demonstrate an alternative or complementary mechanism by which gut bacteria compete for iron in addition to the known siderophoric acquisition systems. Currently the association between iron and bacterial reuterin and DAP pathways is unclear; however, DAP is reported to be a siderophore precursor for several bacteria, and several DAP pathway genes lie in close proximity to siderophore production operons (Burrell et al., 2012; Lynch et al., 2001).

The role of bacteria in FTN regulation was shown previously (Deschemin et al., 2016; Siebert et al., 2015). Consistent with

(G) HRE-based luciferase assay in HEK293 cells transfected with wild-type or the PT-binding site mutant of HIF-2 α and treated with reuterin or PT2385 (PT) (n = 3). All data are mean \pm SEM. t test (B) and (C) or one-way ANOVA with Tukey's multiple comparisons test (E), (F), and (G). Western analyses (D), images were analyzed by ImageJ software from three independent experiments, representative image shown. Statistical significance compared with the DFO-only treatment group. *p < 0.05, **p < 0.01, ***p < 0.001.




Figure 7. DAP and Reuterin Prevent Systemic Iron Accumulation and Antibiotics Improve Anemia in Mouse Models

(A) Schematic showing time line of DAP or *L. reuteri* probiotic treatment in tamoxifen-mediated temporal disruption of hepcidin (*Hamp^{ΔLiv}*).

(B) Serum and tissue (liver, pancreas, and heart) iron analyses.

(C) Duodenal DMT1, Dcytb, and FPN western analyses in DAP- or *L. reuteri*-probiotic-treated *Hamp^{fl/fl}* and *Hamp^{ΔLiv}* mice. Wild-type SPF mice were fed with the 350- or <5-ppm iron diet for 1 week followed by the 350-ppm, <5-ppm, or rifaximin (Rfx) (20 mg/kg/day)-blended <5-ppm diet for another 2 weeks.

(D and E) Duodenal *Dmt1* and *Dcytb* gene expression (D) and CBC (Hb, MCH, and MCHC) analysis (E).

(legend continued on next page)

those reports, our results show that native bacteria are essential in the regulation of local intestinal FTN. In addition, our results demonstrate that intestinal microbiota also play a role in peripheral-tissue FTN regulation. LPS, via activation of NF κ B, is a known regulator of *Ftn* transcription in macrophages (Siegert et al., 2015). Our present results demonstrate a novel mechanism of FTN regulation, as there was no difference in *Ftn* mRNA levels between GF or Abx-treated and control mice. Moreover, host bacterial sensing pathways were not involved in FTN regulation by indigenous microbes. Our results show that a subset of metabolites other than HIF-2 α suppressors regulate host iron-storage function by a novel yet unidentified mechanism. Bacterial metabolite-induced FTN expression provides an additional mechanism by which host iron absorption is decreased, leading to increased levels of luminal iron for resident bacteria. It is possible, however, that the systemic FTN response mediated by gut microbial metabolites reflects a mechanism to sequester iron from pathogens. Further studies are ongoing to identify FTN-regulatory metabolites and determine their physiological relevance.

There are no cures for hemochromatosis, and current maintenance therapies provide a benefit by decreasing tissue-iron accumulation. The two mainstay therapies for hemochromatosis are iron chelators such as DFO and routine phlebotomy, but those therapies are slow acting with many off-target effects, leading to low patient adherence (Adams and Barton, 2007). Our results provide evidence that probiotics may be effective as a stand-alone or adjuvant therapy. Moreover, iron-deficiency anemia is a global health crisis affecting more than a billion people (Lopez et al., 2016). Oral iron supplementation is an effective treatment, but this approach is risky and can even be fatal, especially in third-world countries where infections are endemic (Jonker and Boele van Hensbroek, 2014). Antibiotics have been shown to be effective in improving anemia; however, the improvement was thought to be mainly due to a decrease in bacterial infections (Gifford et al., 2012, 2015). We clearly demonstrate that antibiotics may have additional beneficial effects outside of pathogen control, specifically by increasing intestinal iron absorption.

In summary, our results demonstrate a previously undescribed mechanism of metabolic crosstalk between microbiota and the host intestinal epithelium that regulates intestinal and systemic iron homeostasis. We provide *in vivo* evidence that probiotics may play a beneficial role in diseases of iron overload, whereas antibiotics may be effective in iron deficiency

Limitations of Study

Our data have utilized a mouse model and assessed the role of the microbiota in host nutrient absorption. The data demonstrate that DAP and reuterin are functional metabolites that modulate host iron absorption. These metabolites are also present in human duodenum. However, we have not demonstrated that DAP and reuterin can inhibit HIF-2 α activity in the context of a hu-

man microbiome. Similar to this limitation, we show that *L. johnsonii* and *L. reuteri* respond to changes in luminal iron, these changes have not been assessed in iron-deficient or anemic patients. Additionally, as noted above, we have not identified the exact anatomical source of the gut microbial metabolites. They could be produced more distally and by several different microbial species. It is not possible currently to determine if local or distal sources are responsible for the changes observed in the duodenum. Lastly, mouse models of iron-related disorders do not completely recapitulate the extent of the anemic or iron-overload phenotype observed in humans, further pre-clinical studies are needed to determine if microbial-based therapies could have efficacy in patients.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- LEAD CONTACT AND MATERIALS AVAILABILITY
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Mice
 - Human Subjects
- METHOD DETAILS
 - Cell Culture and Proliferation Assays
 - HIO Culture and Microinjection with Bacteria
 - Bacterial Strains
 - Antibiotics Treatment
 - Metabolite Supplementation
 - Hematological and Iron Analysis
 - Real-Time Quantitative PCR
 - DNA Extraction from Feces and Bacteria-Specific PCR
 - Western Blotting and Co-immunoprecipitation
 - Immunostaining
 - Luciferase Assay
 - Metabolite Extraction
 - 16S RRNA Gene Sequencing and Bacterial Community Analysis
 - Gas Chromatography-Mass Spectrometry Analysis of Metabolites
- QUANTIFICATION AND STATISTICAL ANALYSIS
- DATA AND CODE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.cmet.2019.10.005>.

ACKNOWLEDGMENTS

This work was supported by the NIH, United States (grants CA148828 and DK095201 to Y.M.S. and F31 DK11655 to A.J.S.); the University of Michigan

(F) Schematic showing the integration of HIF-2 α inhibitory and FTN stimulatory roles of gut microbial metabolites to regulate host systemic iron homeostasis. HIF-2 α inhibitory metabolites disrupt the HIF-2 α -ARNT interaction followed by its degradation and subsequent transcriptional downregulation of the intestinal transporters, a different subset of metabolites upregulates FTN expression. Both of these responses can lead to decreased iron absorption.

All data are mean \pm SEM. One-way ANOVA with Tukey's multiple comparisons test (B), (D), and (E). Western analyses (C), images were analyzed by ImageJ software from three independent experiments, representative images are shown. Statistical significance compared with the vehicle-only treatment group. *p < 0.05, **p < 0.01, ***p < 0.001.

Center for Gastrointestinal Research, United States (DK034933); a pilot grant from the University of Michigan, United States–GI Spore (CA130810 to Y.M.S.); the University of Michigan, United States Microbiome Explorer Program, NIAID, United States Novel Alternative Model Systems for Enteric Diseases (NAMESD) consortium (U19AI116482 to M.K.S., J.R.S. and V.B.Y.); NIAID, United States (U01AI124255 to M.K.S. and V.B.Y.) Crohn's & Colitis Foundation, United States Senior Research Award (410234) to N.I.; Clinical and Translational Science Award (CTSA) from The Michigan Institute for Clinical & Health Research (MICHR), United States (UL1TR000433) to D.R.H.; The Pennsylvania Department of Health, United States using Tobacco CURE grant to A.D.P.; and the Spanish Ministry of Science Innovation and Universities, Spain (RTA2017-00002-00-00 to J.L.A.).

AUTHOR CONTRIBUTIONS

N.K.D. and Y.M.S. conceived and designed the study. N.K.D., A.J.S., G.B., N.I., Q.L., J.L.A., J.R.S., G.N., A.D.P., D.S., and V.B.Y. developed the methodologies. N.K.D., A.J.S., G.B., N.I., Q.L., A.S., D.H., X.M., O.L., and M.K.S. acquired the data. N.K.D., A.J.S., G.B., N.I., M.K.S., and Y.M.S. analyzed and interpreted the data. N.K.D. and Y.M.S. wrote the manuscript. Y.M.S. supervised the study.

DECLARATION OF INTERESTS

The authors declare no competing interests.

Received: May 9, 2019

Revised: September 23, 2019

Accepted: October 14, 2019

Published: November 7, 2019

REFERENCES

Adams, P.C., and Barton, J.C. (2007). Haemochromatosis. *Lancet* 370, 1855–1860.

Albenberg, L., Espipova, T.V., Judge, C.P., Bittinger, K., Chen, J., Laughlin, A., Grunberg, S., Baldassano, R.N., Lewis, J.D., Li, H., et al. (2014). Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. *Gastroenterology* 147, 1055–1063.

Anderson, E.R., Taylor, M., Xue, X., Ramakrishnan, S.K., Martin, A., Xie, L., Bredell, B.X., Gardenghi, S., Rivella, S., and Shah, Y.M. (2013). Intestinal HIF2alpha promotes tissue-iron accumulation in disorders of iron overload with anemia. *Proc. Natl. Acad. Sci. USA* 110, E4922–E4930.

Benita, Y., Kikuchi, H., Smith, A.D., Zhang, M.Q., Chung, D.C., and Xavier, R.J. (2009). An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. *Nucleic Acids Res.* 37, 4587–4602.

Bennett, B.D., Yuan, J., Kimball, E.H., and Rabinowitz, J.D. (2008). Absolute quantitation of intracellular metabolite concentrations by an isotope ratio-based approach. *Nat. Protoc.* 3, 1299–1311.

Burrell, M., Hanfrey, C.C., Kinch, L.N., Elliott, K.A., and Michael, A.J. (2012). Evolution of a novel lysine decarboxylase in siderophore biosynthesis. *Mol. Microbiol.* 86, 485–499.

Cai, J., Zhang, J., Tian, Y., Zhang, L., Hatzakis, E., Krausz, K.W., Smith, P.B., Gonzalez, F.J., and Patterson, A.D. (2017). Orthogonal comparison of GC-MS and (1). *Anal. Chem.* 89, 7900–7906.

Chae, T.U., Kim, W.J., Choi, S., Park, S.J., and Lee, S.Y. (2015). Metabolic engineering of *Escherichia coli* for the production of 1,3-diaminopropane, a three carbon diamine. *Sci. Rep.* 5, 13040.

Chen, G., and Chen, J. (2013). A novel cell modification method used in biotransformation of glycerol to 3-HPA by *Lactobacillus reuteri*. *Appl. Microbiol. Biotechnol.* 97, 4325–4332.

Chen, W., Hill, H., Christie, A., Kim, M.S., Holloman, E., Pavia-Jimenez, A., Homayoun, F., Ma, Y., Patel, N., Yell, P., et al. (2016). Targeting renal cell carcinoma with a HIF-2 antagonist. *Nature* 539, 112–117.

Cho, H., Du, X., Rizzi, J.P., Liberzon, E., Chakraborty, A.A., Gao, W., Carvo, I., Signoretti, S., Bruick, R.K., Josey, J.A., et al. (2016). On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models. *Nature* 539, 107–111.

Constante, M., Fragoso, G., Lupien-Meilleur, J., Calvé, A., and Santos, M.M. (2017). Iron supplements modulate colon microbiota composition and potentiate the protective effects of probiotics in dextran sodium sulfate-induced colitis. *Inflamm. Bowel Dis.* 23, 753–766.

Das, N., Xie, L., Ramakrishnan, S.K., Campbell, A., Rivella, S., and Shah, Y.M. (2015). Intestine-specific disruption of hypoxia-inducible factor (HIF)-2alpha improves anemia in sickle cell disease. *J. Biol. Chem.* 290, 23523–23527.

Deschemin, J.C., Noordine, M.L., Remot, A., Willemetz, A., Afif, C., Canonne-Hergaux, F., Langella, P., Karim, Z., Vaulont, S., Thomas, M., et al. (2016). The microbiota shifts the iron sensing of intestinal cells. *FASEB J.* 30, 252–261.

Eigenbrod, T., Park, J.H., Harder, J., Iwakura, Y., and Núñez, G. (2008). Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. *J. Immunol.* 181, 8194–8198.

Fachi, J.L., Felipe, J.S., Pral, L.P., da Silva, B.K., Correa, R.O., de Andrade, M.C.P., da Fonseca, D.M., Basso, P.J., Camara, N.O.S., de Sales, E.S.E.L., et al. (2019). Butyrate protects mice from *Clostridium difficile*-induced colitis through an HIF-1-dependent mechanism. *Cell Rep.* 27, 750–761.

Finkbeiner, S.R., Freeman, J.J., Wieck, M.M., El-Nachef, W., Altheim, C.H., Tsai, Y.H., Huang, S., Dyal, R., White, E.S., Grikscheit, T.C., et al. (2015). Generation of tissue-engineered small intestine using embryonic stem cell-derived human intestinal organoids. *Biol. Open* 4, 1462–1472.

Ghassempour, A., Nojavan, S., Talebpour, Z., Amiri, A.A., and Najafi, N.M. (2004). Monitoring of the fermentation media of citric acid by the trimethylsilyl derivatives of the organic acids formed. *J. Agric. Food Chem.* 52, 6384–6388.

Gifford, A.H., Moulton, L.A., Dorman, D.B., Olbina, G., Westerman, M., Parker, H.W., Stanton, B.A., and O'Toole, G.A. (2012). Iron homeostasis during cystic fibrosis pulmonary exacerbation. *Clin. Transl. Sci.* 5, 368–373.

Gifford, A.H., Dorman, D.B., Moulton, L.A., Helm, J.E., Griffin, M.M., and MacKenzie, T.A. (2015). Serum iron level is associated with time to antibiotics in cystic fibrosis. *Clin. Transl. Sci.* 8, 754–758.

Goddard, A.F., James, M.W., McIntyre, A.S., and Scott, B.B.; British Society of Gastroenterology (2011). Guidelines for the management of iron deficiency anaemia. *Gut* 60, 1309–1316.

Harrison, P.M., and Arosio, P. (1996). The ferritins: molecular properties, iron storage function and cellular regulation. *Biochim. Biophys. Acta* 1275, 161–203.

Hill, D.R., Huang, S., Nagy, M.S., Yadagiri, V.K., Fields, C., Mukherjee, D., Bons, B., Dedhia, P.H., Chin, A.M., Tsai, Y.H., et al. (2017). Bacterial colonization stimulates a complex physiological response in the immature human intestinal epithelium. *Elife* 6, e29132.

Jaeggi, T., Kortman, G.A., Moretti, D., Chassard, C., Holding, P., Dostal, A., Boekhorst, J., Timmerman, H.M., Swinkels, D.W., Tjalsma, H., et al. (2015). Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. *Gut* 64, 731–742.

Jonker, F.A., and Boele van Hensbroek, M. (2014). Anaemia, iron deficiency and susceptibility to infections. *J. Infect.* 69, S23–S27.

Kelly, C.J., Zheng, L., Campbell, E.L., Saeedi, B., Scholz, C.C., Bayless, A.J., Wilson, K.E., Glover, L.E., Kominsky, D.J., Magnuson, A., et al. (2015). Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function. *Cell Host Microbe* 17, 662–671.

Koenigsnecht, M.J., Baker, J.R., Wen, B., Frances, A., Zhang, H., Yu, A., Zhao, T., Tsume, Y., Pai, M.P., Bleske, B.E., et al. (2017). In vivo dissolution and systemic absorption of immediate release ibuprofen in human gastrointestinal tract under fed and fasted conditions. *Mol. Pharm.* 14, 4295–4304.

Lin, L., and Zhang, J. (2017). Role of intestinal microbiota and metabolites on gut homeostasis and human diseases. *BMC Immunol.* 18, 2.

Lopez, A., Cacoub, P., Macdougall, I.C., and Peyrin-Biroulet, L. (2016). Iron deficiency anaemia. *Lancet* 387, 907–916.

- Lynch, D., O'Brien, J., Welch, T., Clarke, P., Cuív, P.O., Crosa, J.H., and O'Connell, M. (2001). Genetic organization of the region encoding regulation, biosynthesis, and transport of rhizobactin 1021, a siderophore produced by *Sinorhizobium meliloti*. *J. Bacteriol.* *183*, 2576–2585.
- Ma, X., Shah, Y.M., Guo, G.L., Wang, T., Krausz, K.W., Idle, J.R., and Gonzalez, F.J. (2007). Rifaximin is a gut-specific human pregnane X receptor activator. *J. Pharmacol. Exp. Ther.* *322*, 391–398.
- Malo, C. (1994). Free amino acid levels in serum and small intestine during the post-natal development of normal and sparse-fur mutant mice. *Comp. Biochem. Physiol. A Physiol.* *109*, 1049–1057.
- Mancias, J.D., Wang, X., Gygi, S.P., Harper, J.W., and Kimmelman, A.C. (2014). Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. *Nature* *509*, 105–109.
- Martin, C.R., Osadchiy, V., Kalani, A., and Mayer, E.A. (2018). The brain-gut-microbiome axis. *Cell. Mol. Gastroenterol. Hepatol.* *6*, 133–148.
- Matsumoto, M., Kibe, R., Ooga, T., Aiba, Y., Kurihara, S., Sawaki, E., Koga, Y., and Benno, Y. (2012). Impact of intestinal microbiota on intestinal luminal metabolome. *Sci. Rep.* *2*, 233.
- Matsumoto, M., Ooga, T., Kibe, R., Aiba, Y., Koga, Y., and Benno, Y. (2017). Colonic absorption of low-molecular-weight metabolites influenced by the intestinal microbiome: a pilot study. *PLoS One* *12*, e0169207.
- Montiel. (2014). Antimicrobial activity of reuterin produced by *Lactobacillus reuteri* on *Listeria monocytogenes* in cold-smoked salmon. *Food Microbiology* *44* (December 2014).
- Parsons, D.S., and Shaw, M.I. (1983). Use of high performance liquid chromatography to study absorption and metabolism of purines by rat jejunum in vitro. *Q. J. Exp. Physiol.* *68*, 53–67.
- Pickard, J.M., Zeng, M.Y., Caruso, R., and Núñez, G. (2017). Gut microbiota: role in pathogen colonization, immune responses, and inflammatory disease. *Immunol. Rev.* *279*, 70–89.
- Ramakrishnan, S.K., Anderson, E.R., Martin, A., Centofanti, B., and Shah, Y.M. (2015). Maternal intestinal HIF-2alpha is necessary for sensing iron demands of lactation in mice. *Proc. Natl. Acad. Sci. USA* *112*, E3738–E3747.
- Ramakrishnan, S.K., Zhang, H., Ma, X., Jung, I., Schwartz, A.J., Triner, D., Devenport, S.N., Das, N.K., Xue, X., Zeng, M.Y., et al. (2019). Intestinal non-canonical NFkappa B signaling shapes the local and systemic immune response. *Nat. Commun.* *10*, 660.
- Salim, E.I., Wanibuchi, H., Morimura, K., Kim, S., Yano, Y., Yamamoto, S., and Fukushima, S. (2000). Inhibitory effects of 1,3-diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine. *Carcinogenesis* *21*, 195–203.
- Sanchez, M., Galy, B., Muckenthaler, M.U., and Hentze, M.W. (2007). Iron-regulatory proteins limit hypoxia-inducible factor-2alpha expression in iron deficiency. *Nat. Struct. Mol. Biol.* *14*, 420–426.
- Schaefer, L., Auchtung, T.A., Hermans, K.E., Whitehead, D., Borhan, B., and Britton, R.A. (2010). The antimicrobial compound reuterin (3-hydroxypropionaldehyde) induces oxidative stress via interaction with thiol groups. *Microbiology* *156*, 1589–1599.
- Schott, K., Huether, G., and Neuhoff, V. (1983). Free amino acid concentrations in the gut lumen of developing rats. *Biochem. Med.* *29*, 285–292.
- Schwartz, A.J., Das, N.K., Ramakrishnan, S.K., Jain, C., Jurkovic, M.T., Wu, J., Nemeth, E., Lakhal-Littleton, S., Colacino, J.A., and Shah, Y.M. (2019). Hepatic hepcidin/intestinal HIF-2alpha axis maintains iron absorption during iron deficiency and overload. *J. Clin. Invest.* *129*, 336–348.
- Shah, Y.M., Matsubara, T., Ito, S., Yim, S.H., and Gonzalez, F.J. (2009). Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. *Cell Metab.* *9*, 152–164.
- Shankar, V., Gouda, M., Moncivaiz, J., Gordon, A., Reo, N.V., Hussein, L., and Paliy, O. (2017). Differences in gut metabolites and microbial composition and functions between Egyptian and U.S. Children are consistent with their diets. *mSystems* *2*, e00169.
- Siebert, I., Schödel, J., Nairz, M., Schatz, V., Dettmer, K., Dick, C., Kalucka, J., Franke, K., Ehrenschwender, M., Schley, G., et al. (2015). Ferritin-mediated iron sequestration stabilizes hypoxia-inducible factor-1alpha upon LPS activation in the presence of ample oxygen. *Cell Rep.* *13*, 2048–2055.
- Smith, P.M., Howitt, M.R., Panikov, N., Michaud, M., Gallini, C.A., Bohlooly-Y, M., Glickman, J.N., and Garrett, W.S. (2013). The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* *341*, 569–573.
- Sridharan, G.V., Choi, K., Klemashevich, C., Wu, C., Prabakaran, D., Pan, L.B., Steinmeyer, S., Mueller, C., Yousofshahi, M., Alaniz, R.C., et al. (2014). Prediction and quantification of bioactive microbiota metabolites in the mouse gut. *Nat. Commun.* *5*, 5492.
- Talarico, T.L., and Dobrogosz, W.J. (1989). Chemical characterization of an antimicrobial substance produced by *Lactobacillus reuteri*. *Antimicrob. Agents Chemother.* *33*, 674–679.
- Taylor, M., Qu, A., Anderson, E.R., Matsubara, T., Martin, A., Gonzalez, F.J., and Shah, Y.M. (2011). Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. *Gastroenterology* *140*, 2044–2055.
- Vanoaica, L., Darshan, D., Richman, L., Schumann, K., and Kühn, L.C. (2010). Intestinal ferritin H is required for an accurate control of iron absorption. *Cell Metab.* *12*, 273–282.
- Wallace, E.M., Rizzi, J.P., Han, G., Wehn, P.M., Cao, Z., Du, X., Cheng, T., Czerwinski, R.M., Dixon, D.D., Goggin, B.S., et al. (2016). A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma. *Cancer Res.* *76*, 5491–5500.
- Wang, Z., Klipfell, E., Bennett, B.J., Koeth, R., Levison, B.S., Dugar, B., Feldstein, A.E., Britt, E.B., Fu, X., Chung, Y.M., et al. (2011). Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* *472*, 57–63.
- Wikoff, W.R., Anfora, A.T., Liu, J., Schultz, P.G., Lesley, S.A., Peters, E.C., and Siuzdak, G. (2009). Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proc. Natl. Acad. Sci. USA* *106*, 3698–3703.
- Xue, X., Taylor, M., Anderson, E., Hao, C., Qu, A., Greenson, J.K., Zimmermann, E.M., Gonzalez, F.J., and Shah, Y.M. (2012). Hypoxia-inducible factor-2alpha activation promotes colorectal cancer progression by dysregulating iron homeostasis. *Cancer Res.* *72*, 2285–2293.

STAR★METHODS

KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---|-------------------------------------|--|
| Antibodies | | |
| HIF-1 α | Abcam | Cat# 179483; RRID:AB_2732807; 1:1000 |
| HIF-2 α | Bethyl Laboratories | Cat# A700-003; RRID:AB_2631884; 1:1000 |
| FTH1 | Cell Signaling Technology | Cat# 3998; RRID:AB_1903974; 1:1000 |
| FPN | Alpha Diagnostics International | Cat# MTP11-A; RRID:AB_1619475; 1:1000 |
| DMT1 | Alpha Diagnostics International | Cat# NRAMP21-A; RRID:AB_1620356; 1:1000 |
| DCYTB | Alpha Diagnostics International | Cat# DCYTB11-A; RRID:AB_1614641; 1:1000 |
| ARNT | Santa Cruz Biotechnology | Cat# sc-8076; RRID:AB_2059435; 1:1000 |
| GAPDH | Santa Cruz Biotechnology | Cat# sc-25778; RRID:AB_10167668; 1:1000 |
| Actin | Proteintech | Cat# 60008-1-Ig; RRID:AB_2289225; 1:1000 |
| Rabbit IgG HRP-linked | Cell Signaling Technology | Cat# 7074; RRID:AB_2099233; 1:2000 |
| Mouse IgG HRP-linked | Cell Signaling Technology | Cat# 7076; RRID:AB_330924; 1:2000 |
| Goat IgG HRP-linked | ThermoFisher | Cat# PA1-28664; RRID:AB_10990162; 1:1000 |
| Rabbit IgG Alexa Fluor 594 | ThermoFisher | Cat# A-11037; RRID:AB_2534095; 1:500 |
| Chemicals | | |
| Deferoxamine | Sigma | D9533 |
| Ferric ammonium citrate | Sigma | F5879 |
| Ferrozine | Sigma-Aldrich | 160601 |
| Iron Standard Solution | Acros Organics | 19605-1000 |
| Mercaptoacetic acid | Acros Organics | AC125430100 |
| Matrigel | BD Biosciences | 354234 |
| Noggin | R&D Systems | 6057-NG |
| Rspondin1 | R&D Systems | 4645-RS |
| Epidermal growth factor | R&D Systems | 236-EG |
| MTT reagent | Alfa Aesar | L11939 |
| PT2385 | MedChemExpress | HY12867 |
| Ampicillin | Sigma-Aldrich | A9393 |
| Neomycin | Sigma-Aldrich | N1876 |
| Gentamicin | Sigma-Aldrich | G1914 |
| Penicillin G | Sigma-Aldrich | P7794 |
| Metronidazole | Sigma-Aldrich | M1547 |
| Vancomycin | Cayman Chemical | 15327 |
| Rifaximin | Cayman Chemical | 16131 |
| Trizol | ThermoFisher | 15596018 |
| Methanol | Fisher Scientific | A412-500 |
| Chloroform | Fisher Scientific | BP1145-1 |
| Halt™ Protease Inhibitor Cocktail | ThermoFisher | 78429 |
| SYBR green qPCR master mix | Radiant™ | QS2001 |
| Prolong™ Gold Antifade Mountant with DAPI | ThermoFisher | P36931 |
| GFP-Trap magnetic beads | Chromotek | gtma-10 |
| Polyethylenimine (PEI) | Polysciences Inc. | 23966 |
| DMEM | ThermoFisher | 11995065 |
| Microbial Metabolites | Please see Table S2 | Please see Table S2 |

(Continued on next page)

| Continued | | |
|---|---|---|
| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
| Oligonucleotides | | |
| For the complete list of primers | Please see Table S3 | N/A |
| Bacterial Strains | | |
| <i>Escherichia coli</i> strain ECOR2 | Hill et al., 2017 | ATCC35321 |
| <i>Lactobacillus reuteri</i> strain MM4-1A | Hill et al., 2017 | PTA5475, ATCC |
| <i>L. reuteri</i> probiotic | BioGaia | DSM 17938 |
| <i>L. reuteri</i> for reuterin production | Montiel, 2014 | <i>L. reuteri</i> P579 |
| Recombinant DNA | | |
| Oxygen Stable pCDNA3-HIF-1 α | Yatrik Shah Laboratory (Shah et al., 2009) | N/A |
| Oxygen Stable pCDNA3-HIF-2 α | Shah et al., 2009 | N/A |
| HIF-2 α -IRE Luc | Sanchez et al., 2007 | N/A |
| pGL3-DMT1 Luc (HRE-Luc) | Shah et al., 2009 | N/A |
| pBIND-HIF-2 α | This manuscript | N/A |
| pACT-ARNT | This manuscript | N/A |
| pCDNA3HIF-2 α G324E+S305M | This manuscript | N/A |
| Critical Commercial Assays | | |
| CheckMate™ Mammalian Two-Hybrid System | Promega | E2440 |
| Luciferase Assay | Promega | E1500 |
| MiSeq Reagent Kit v2 (500-Cycles) | Illumina | 20038613. Cartridge# MS3983770-500V2 |
| DNeasy Blood and Tissue Kit | Qiagen | 69504 |
| SuperScript™ III First-Strand Synthesis System | ThermoFisher | 18080051 |
| Software and Algorithms | | |
| Prism | GraphPad Version 7.0 | N/A |
| ImageJ | https://imagej.nih.gov/ij/ | N/A |
| Bacterial community analysis | Mothur Wiki | N/A |
| Deposited Data | | |
| 16S rRNA gene sequencing reads | NCBI BioProject ID | PRJNA576605 |
| Experimental Models: Cell Lines | | |
| HCT116 | ATCC | N/A |
| SW480 | ATCC | N/A |
| HT29 | ATCC | N/A |
| HEK293 | ATCC | N/A |
| Experimental Models: Mouse Strains | | |
| C56Bl/6J | The Jackson Laboratory | N/A |
| C56Bl/6J, Germ Free | The Jackson Laboratory | N/A |
| NCOA4 ^{-/-} | This manuscript | N/A |
| <i>Hif2α</i> ^{ΔIE;Vil^{Cre};Hif2α^{F/F}} | Shah et al., 2009 | N/A |
| <i>Vhl</i> ^{ΔIE;Vil^{Cre};Vhl^{F/F}} | Shah et al., 2009 | N/A |
| <i>Hamp</i> ^{ΔLiv;Alb^{CreERT2};Hamp^{F/F}} | Schwartz et al., 2019 | N/A |
| <i>Tlr2/4</i> ^{-/-} | Eigenbrod et al., 2008 | N/A |
| <i>Myd88</i> ^{-/-} | Eigenbrod et al., 2008 | N/A |
| Other | | |
| Standard Chow | PMI Nutrition Int'l | LABDIET 5001 |
| 350 ppm iron Chow | Dyets Inc. | 115180 |
| 35 ppm iron Chow | Dyets Inc. | 115270 |
| <5 ppm iron Chow | Dyets Inc. | 115072 |

LEAD CONTACT AND MATERIALS AVAILABILITY

A new construct was generated in this study : mouse HIF-2 α mutant of two PT2399 binding sites (pCDNA3-HIF-2 α G324E+S305M). And a new mouse line generated in this study : NCOA4^{-/-}. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Yatrik Shah (shahy@umich.edu). All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice

All mice used in this study were on a C57BL/6J background. Both male and female mice were used throughout and littermates were randomly assigned to experimental groups. The GF mice were housed in a temperature-controlled (21 \pm 1.1 $^{\circ}$ C), barrier facility using individual Isocages[®] (Tecniplast) in the University of Michigan Germ-Free Mouse Core. All other mice were housed in a temperature-controlled (21 \pm 1.1 $^{\circ}$ C), specific-pathogen free (SPF) facility on a 12 h light/dark cycle and fed ad libitum with standard chow diet containing 270 ppm iron. For iron studies, mice were fed with iron enriched (350 ppm iron), iron sufficient (35 ppm iron) or low-iron (<5 ppm iron) chow for the 1-2 weeks. There was no significant gender differences with regards to their iron status as reported previously (Schwartz et al., 2019). NCOA4^{-/-} mice were generated by the University of Michigan Transgenic Core using CRISPR-cas9 mediated targeting of exon 3 (guide RNA: 5'-AGAGGTGTGGCTCAATGAAC-3'). Intestine-specific HIF-2 α knockout (*Hif2 α* ^{Δ IE;Vil^{Cre};Hif2 α ^{F/F}}), intestine-specific VHL knockout (*Vhl* ^{Δ IE;Vil^{Cre};Vhl^{F/F}}), liver-specific tamoxifen-inducible hepcidin knockout (*Hamp* ^{Δ Liv;Alb^{CreERT2};Hamp^{F/F}}), *Tlr2/4*^{-/-} and *Myd88*^{-/-} mice were described previously (Eigenbrod et al., 2008; Schwartz et al., 2019; Shah et al., 2009). All animal studies were carried out in accordance with Association for Assessment and Accreditation of Laboratory Animal Care International guidelines and approved by the University Committee on the Use and Care of Animals at the University of Michigan.

Human Subjects

For detection of lactobacillus in the upper gastrointestinal tract of humans, duodenal aspirates were collected from 17 healthy subjects from a previously reported study group (Koenigsnecht et al., 2017). Physiological concentrations of 1,3 DAP and reuterin were determined from 10 subjects from the same group. The study is a part of clinical trial NCT02806869 and was approved by the institutional review boards at the University of Michigan (IRB MED, protocol number HUM00085066) and the Department of Health and Human Services, Food and Drug Administration (Research Involving Human Subjects Committee/RIHSC, protocol number 14-029D). The study was carried out in accordance with the protocol and applicable local regulatory requirements. All subjects (both male and female, age 18-55 years) provided written informed consents and participated after completion of a physical examination and review of their previous medical history.

METHOD DETAILS

Cell Culture and Proliferation Assays

Human intestinal cell lines HCT116, HT29 and SW480, and human embryonic kidney cells HEK293T were used. All cells were maintained in complete DMEM medium (supplemented with 10% fetal bovine serum and 1% antibiotic/antimycotic agent) at 37 $^{\circ}$ C in 5% CO₂ and 21% O₂. For hypoxic experiments, cells were maintained in 1% O₂ in an enclosed humidified chamber by replacing the atmospheric air with a gas mixture comprising of 1% O₂, 5% CO₂ and 95% N₂. Growth assays were performed using MTT reagent (Thiazolyl Blue Tetrazolium Bromide). Briefly, cells were plated down and 24-hours following plating a Day 0 reading was taken. Cells were incubated for 45 minutes with MTT solution (5X concentrate stock: 5 mg/ml, in 1XPBS, pH 7.4). Media and MTT solution were then carefully aspirated followed by solubilization with dimethyl sulfoxide. Absorbance was read at 570nm. Following the Day 0 read, the cells were treated with different doses of DAP doses and readings were taken after 24-hours.

HIO Culture and Microinjection with Bacteria

Differentiated human intestinal organoid (HIO)s were generated from human pluripotent stem cell (hPSC)s, maintained and used for microinjection with commensal bacterial culture as described previously (Hill et al., 2017). HIOs were maintained in media containing EGF, Noggin, and R-spondin (ENR media) in 60 μ l Matrigel (8 mg/ml) without antibiotics prior to microinjection experiments. For hypoxia experiments, HIOs were put in a hydrated and sealed chamber filled with 1% O₂, 5% CO₂, and balance N₂ and maintained at 37 $^{\circ}$ C for 16 hours. HIO microinjection with PBS, live- or heat killed *E. coli* were performed under microscopic guidance with the aid of thin wall glass capillaries (TW100F-4, World Precision Instruments) after shaping them with a P-30 micropipette puller (Sutter Instruments). After the microinjection, the HIO culture media was carefully aspirated and the wells were rinsed with sterile PBS and maintained in ENR media containing penicillin and streptomycin to remove any bacteria.

Bacterial Strains

For HIO colonization and bacterial growth analysis, *E. coli* strain ECOR2 (ATCC 35321; Originally isolated from healthy adult stool sample, gift of Dr. Seth Walk, Montana State University) and *L. reuteri* strain MM4-1A (PTA5475, ATCC; Originally isolated

from human breast milk, gift of Dr. Robert Britton, Baylor College of Medicine) were used as described previously (Hill et al., 2017). The bacteria were cultured in Luria broth (LB) media at 37°C under atmospheric oxygen concentration.

Antibiotics Treatment

Antibiotics treatment (Abx) was performed as described previously (Ramakrishnan et al., 2019). Briefly, animals were given water containing antibiotic cocktail (Ampicillin 1 g/L, neomycin 1 g/L, gentamycin 500 mg/L; penicillin 100U/L) in the drinking water, ad libitum. In addition, oral gavage of vancomycin (1 mg/mL) and metronidazole (0.5 mg/mL) was given on alternate days for 1-2 weeks. Rifaximin was blended with <5-ppm iron diet and administered at 20 mg/kg body weight/day as described previously (Ma et al., 2007).

Metabolite Supplementation

Sodium salts of butyrate and propionate were given in drinking water at 150mM and 100mM concentrations, respectively (Smith et al., 2013). 1,3 Diaminopropane was given in drinking water at a concentration of 2g/L (Salim et al., 2000). For reuterin supplementation of mouse gut, *L. reuteri* probiotic tablets containing *L. reuteri* DSM17938 probiotic strain (100 million CFU per tablet) was added in drinking water (1 tablet per 200 ml).

Hematological and Iron Analysis

CBC (complete blood count) analysis was performed by the Unit for Laboratory Animal Medicine Pathology Core at The University of Michigan. Serum and tissue nonheme iron was quantified as described previously (Anderson et al., 2013). Briefly, serum and homogenized tissues were processed in a 1M HCl and 10% (wt/ vol) trichloroacetic acid solution and heated for 1 h at 95°C. The samples were spun at 13,000 rpm, room temperature for 20 minutes, then the supernatant was incubated with an iron assay reagent ((1:1, 1mM ferrozine : 3M Sodium Acetate, pH 5.5) plus 1% mercaptoacetic acid) at 1:1 ratio until the color turns into purple. Iron quantitation was done at 562 nm and compared with iron standard solution (1 mg/ml Fe in 2% HNO₃).

Real-Time Quantitative PCR

1 µg of total RNA extracted using Trizol reagent from mouse tissues (duodenal epithelial scrapes, liver and spleen), human intestinal cell lines and human intestinal organoid (HIO)s were reverse transcribed to cDNA using SuperScript™ III First-Strand Synthesis System (Invitrogen). Quantitative PCR (qPCR) reactions were set up in three technical replicates for each sample by combining equal concentration of cDNA, gene-specific forward and reverse primers, with SYBR green master mix, and run in QuantStudio 5 Real-Time PCR System (Applied Biosystems). The fold-change of the genes were calculated using the $\Delta\Delta C_t$ method using β -actin as the housekeeping gene. The primers are listed in Table S3.

DNA Extraction from Feces and Bacteria-Specific PCR

DNA from mouse feces was extracted by using DNeasy Blood and Tissue Kit. 0.5–1.0 ng of DNA was used for bacteria-specific PCR, relative abundance was determined after normalization with the readings from the value from PCR by pan-bacteria primers. The primers are listed in Table S3.

Western Blotting and Co-immunoprecipitation

Whole-cell and membrane lysate preparations were described previously (Anderson et al., 2013). Whole-cell lysates were prepared from tissue or cell lines by RIPA buffer. Briefly, Cell or tissue homogenates were incubated in RIPA buffer for 15–20 minutes on ice followed by centrifugation at 13,000 rpm for 15 minutes at 4°C. Supernatants were transferred to a new tube and mixed with 5× Laemmli buffer and boiled for 5 min. Membrane lysate was prepared by dounce homogenization of scraped duodenal epithelia followed by passaging the samples through a 27-gauge needle 7-10 times in lysis buffer (5mM Tris pH 8.0, 2mM EDTA, 250mM of sucrose and protease inhibitor). The nuclei were pelleted at 1,000 × g for 10 minutes, and the supernatant was centrifuged at 45,000 × g for 45 minutes using Optima™ TLX Ultracentrifuge (Beckman). The resulting membrane pellet was resuspended in storage buffer (75mM Tris pH 8.0, 12.5mM MgCl₂, 5mM EDTA and protease inhibitor). Membrane extracts were mixed with 2X Laemmli buffer and incubated at 42°C for 5 min. Co-immunoprecipitation experimental procedure was performed with GFP-Trap magnetic beads and is summarized in Figure 4D. Lysates containing 30-40 µg of protein per well were separated by SDS-PAGE, transferred onto nitrocellulose membranes, and immunoblotted overnight at 4°C with antibodies against HIF-2 α , HIF-1 α , FTH1, FPN, DMT1, DCYTB, ARNT, Actin and GAPDH. All the primary antibodies were used at a dilution of 1:1000. HRP-conjugated secondary antibodies used were: anti-rabbit anti-mouse and anti-goat at dilution of 1: 2000, and immunoblots were developed using chemidoc touch imaging system (ChemiDoc, BioRad).

Immunostaining

OCT-embedded frozen tissues were sectioned (6 µm) and fixed with PBS-buffered formalin for 15 min and permeabilized for 10 min using 0.05% Triton X-100. Sections were blocked in 5% (vol/vol) normal goat serum in TBST for 30 min at room temperature and probed with polyclonal rabbit anti-HIF-2 α antibody (1: 100) overnight at 4°C. The samples were then incubated with rabbit IgG Alexa Fluor 594 (1: 500) for 1 hour in dark at room temperature, followed by mounting and counterstaining by Prolong™ Gold Antifade Mountant with DAPI.

Luciferase Assay

Cells were seeded into a 24-well plate at a cell density of 5×10^4 cells per well. The luciferase constructs for HIF response element (HRE) and HIF-2 α IRE were previously described (Sanchez et al., 2007; Shah et al., 2009). The luciferase constructs were co-transfected with oxygen stable HIF-2 α , HIF-1 α or empty vector (EV) into cells with polyethylenimine. To screen the most abundant gut microbial metabolites for HIF-2 α inhibition, a DMT1 promoter luciferase construct harboring HIF response elements (HRE) (hereafter referred to as HRE-Luc) was performed in HCT116 cells. We narrowed our search to metabolites that generated statistically significant ($p < 0.05$) inhibition of HRE-Luc activity by 0.3-fold or greater. To investigate the role of indicated metabolites in HIF-2 α -ARNT interaction, pG5 luciferase vector was co-transfected with pBIND- HIF-2 α and pACT-ARNT into cells using the protocol described in CheckMate™ Mammalian Two-Hybrid System (Promega). To identify the mechanism how indicated metabolites influenced HIF-2 α -ARNT interaction, two PT2399 binding sites in the mouse HIF-2 α was mutated to generate mHIF-2 α G324E+S305M and HRE luciferase assay was performed. Cells were lysed in reporter lysis buffer, and firefly luciferase activity was measured using Synergy™ 2 Multi-Mode Microplate Reader (BioTek) and normalized to β -galactosidase (β -gal) activity 48 hours after transfection.

Metabolite Extraction

Metabolites from mouse duodenal contents and feces were extracted by two methods. First, crude metabolites were extracted by 80% methanol [methanol: water (80:20; v/v)] extraction as described previously (Bennett et al., 2008). Briefly, pre-weighed freshly collected sample were homogenized in 3-5 ml of dry ice-cold 80% methanol and incubated in dry ice for 10 minutes followed by centrifugation at 4,000 rpm for 10 minutes at 4°C. Supernatant was passed through a 70- μ m cell strainer to get rid of the debris and centrifuged again at 13,000 rpm for 10 minutes at 4°C. Supernatant was then transferred to a new sample tube and subjected to Speedvac (Eppendorf Vacufuge) to obtain a metabolite pellet. Second, for physicochemical characterization, metabolites were extracted in organic and aqueous phases using methanol-chloroform-water extraction method as described previously (Sridharan et al., 2014). Briefly, 3-5 ml of dry ice-cold methanol/chloroform (2:1, v/v) was added to a sample tube containing a pre-weighed freshly collected sample. After homogenization on ice, the sample tube was centrifuged at 13,000 rpm for 10 min at 4°C. The supernatant was then transferred to a new sample tube through a (70- μ m) cell strainer. In a dry ice-cold sample tube, 0.6 ml of ice-cold water was added to 1.5 ml of supernatant, the sample tube was vortexed vigorously for 30 seconds and centrifuged at 13,000 rpm for 10 min at 4°C to obtain phase separation. The upper and lower phases were separately collected into fresh sample tubes without disturbing the interface, followed by Speedvac procedure. The metabolite pellets were suspended in DMSO and corn oil (5 mg/100 μ l) for *in vitro* experiments and *in vivo* intraperitoneal injections, respectively.

16S rRNA Gene Sequencing and Bacterial Community Analysis

Bacterial sequencing analysis was done as described previously at the Microbial Systems Molecular Biology Lab, a part of the University of Michigan Host Microbiome Initiative (Ramakrishnan et al., 2019). Briefly, the V4 region of the 16S rRNA gene was amplified from the mouse duodenal contents or feces using the Dual-indexing sequencing strategy. Sequencing was done on the Illumina MiSeq platform, using a MiSeq Reagent Kit V2 500 cycles, according to the manufacturer's instructions with modifications. Bacterial community analysis was done based on Mothur wiki.

Gas Chromatography-Mass Spectrometry Analysis of Metabolites

Extraction and Derivatization Method for DAP

10 mg of sample was mixed with 150 μ L of 6% TCA solution (containing 10 μ g/mL 2,3-¹³C₂ Alanine), homogenized at 6500 rpm, 25 s, with 1.0 mm diameter beads added and then centrifuged at 20,000 RCF for 10 min at 4°C, the supernatant liquor was collected in glass vial and mixed with 300 μ L 50mM Sodium hydroxide solution and 300 μ L propanol/pyridine (v:v=3:2). 100 μ L of propylchloroformate subsequently was added on ice following a vortex for 1 min. The samples were derivatized in an incubator at 35°C for 30 min. The derivatized samples were extracted with 75 μ L of hexane twice, then a total of 150 μ L of extracts was obtained and stored at 4°C for GC-MS analysis.

Extraction and Derivatization Method for Reuterin

10 mg of sample was mixed with 5 μ L of 1 mM 2,2,4,4 - D₄ citric acid and 500 μ L of cold 80% methanol, homogenized at 6500 rpm, 25 s, with 1.0 mm diameter beads added. 200 μ L each of cold water and chloroform are added and homogenized again followed by centrifuging at 20,000 RCF for 10 min at 4°C, the supernatant liquor was collected and transferred into 1.8 mL glass vial and dry down in vacuum speeder. The dried sample was mixed with each 50 μ L pyridine and MSTFA followed by a vortex for 5 min, the samples were derivatized in -20°C refrigerator overnight. Glass vial containing sample was sonicated for 30 min and then centrifuged at 20,000 RCF for 10 min at 4°C, supernatant liquor was collected and stored at 4°C for GC-MS analysis.

GC-MS Method

For DAP, a headspace sampler was utilized, for reuterin a standard GC/MS sampling was performed. A HP5 ms (5%Phenylmethylpolysiloxane) capillary GC column (30 m x 250 μ m i.d. 0.25 μ m film thickness, Agilent Technologies) was employed with helium as the carrier gas at a constant flow rate of 1 mL/min. The initial column oven temperature was 70°C for 2 min and then increased to 230°C at a rate of 20°C/min. The temperatures of the front inlet, transfer line and mass source were set at 250°C, 280°C, and 230°C, respectively. The total run time was 20 min and the mass spectral data was collected in full scan mode with a mass range 30-400 m/z.

injection volume is 1 μ L. 2,2,4,4 - D₄ citric acid and reuterin were quantified by peak areas of extracted m/z 276 (Ghassempour et al., 2004) and m/z 219 (Talarico and Dobrogosz, 1989), respectively as described previously. Analysis of intestinal SCFAs was done as described previously (Cai et al., 2017).

QUANTIFICATION AND STATISTICAL ANALYSIS

Main *in vitro* experiments were validated by multiple cell lines. Each cell line experiment was performed with duplicate or triplicates for each condition and repeated at least three times to ensure reproducibility. Blinding was performed whenever deemed to be appropriate and applicable. Sample description and identification was unavailable to the core personnel during data plotting and analyses. No sample or data was excluded from the study for statistical purposes. Statistical details of all experiments can be found in the figure legends. The sample numbers are mentioned in the figures and denote biological replicates unless otherwise noted. Results are expressed as the mean \pm SEM. Significance between 2 groups was tested using a 2-tailed, unpaired *t* test. Significance among multiple groups was tested using a one-way ANOVA followed by Tukey's post hoc test. GraphPad Prism 7.0 was used to conduct the statistical analyses. Statistical significance is described in the figure legends as: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

DATA AND CODE AVAILABILITY

The accession number for the 16S rRNA gene sequencing data of duodenal and fecal microbiota from mice fed with different iron diets reported in this paper is NCBI BioProject: PRJNA576605.